The use of phthalocyanines and related complexes in photodynamic therapy

Photosensitizers in Medicine, Environment, and Security

Volumn 9789048138722, Issue , 2012, Pages 315-349

  Ion, Rodica Mariana ^a,b  

^a NATIONAL RESEARCH AND DEVELOPMENT INSTITUTE FOR CHEMISTRY AND PETROCHEMISTRY ICECHIM   (Romania)

^b VALAHIA UNIVERSITY OF TARGOVISTE   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOBLEACHING; PHOTOSENSITIZERS; PORPHYRINS; QUANTUM THEORY;

FLUORESCENCE QUANTUM YIELD; PHOTOCHEMICAL EFFICIENCY; PHOTODYNAMIC ACTIVITIES; PHOTOPHYSICAL PROPERTIES; RELATED COMPOUNDS; SINGLET OXYGEN; TRIPLET LIFETIMES; TRIPLET STATE;

PHOTODYNAMIC THERAPY;

EID: 84930915836     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-3872-2_6     Document Type: Chapter

References (191)

1. Ion RM (2003) Porphyrins and photodynamic therapy of cancer. FMR, Bucharest
2. Dalla Via L, Marciani Magno S (2001) Photochemotherapy in the treatment of cancer. Curr Med Chem 8:1405-1518
3. Kessel D (2004) Photodynamic therapy: from the beginning. Photodiagn Photodyn Ther 1:3-14
4. Ion RM (2000) Porphyrins for tumor destruction in photodynamic therapy. Curr Top Biophys 24:21-34
5. Allison RR, Downie GH, Cuenca R et al (2004) Photosensitizers in clinical PDT. Photodiagn Photodyn Ther 1:27-37
6. Frakowiak D, Planner A et al (1998) Incorporation of dye in resting and stimulated leukocytes. In: Daechne S (ed) Near infrared dyes for high technology applications. Kluwer, Dordrecht/ Boston/London
7. Plaetzer K, Kiesslich T, Oberdanner CB et al (2005) Apoptosis following photodynamic tumor therapy: induction, mechanisms and detection. Curr Pharm Des 11(9):1151-1165
8. Almeida RD, Manadas BJ, Carvalho AP et al (2004) Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 1704:59-86
9. Oleinick NL, Morris RL, Belichenko I (2002) The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 1:1-21, 22-24
10. Ion RM, Planner A, Wicktorowicz K et al (1998) The incorporation of various porphyrins into blood cells measured viaflow cytometry, absorption and emission spectroscopy. Acta Biochim Pol 45:833-845
11. Ben-Hur E, Rosental I (1985) Phthalocyanines: A new class of mammalian cells photosensitizers with a potential for cancer phototherapy. Int J Radiat Biol Relat Stud Phys Chem Med 47:145-147
12. Rosenthal I (1991) Phtalocyanines as photodynamic sensitizers. Photochem Photobiol 53:859-870
13. Allen C, Sharman W, Van Lier J (2001) Current status of phthalocyanines in the photodynamic therapy of cancer. J Porphyr Phthalocyanines 5:161-169
14. Leznof CC, Lever ABP (1989) Phthalocyanines, properties and applications, vols 1-39. VCH Publishers, New York
15. (a) Smith KM (1975) Synthesis and preparation of porphyrin compounds. Elsevier, Amsterdam;
16. (b) Moser JG (1998) In: Moser JG (ed) Photodynamic tumor therapy. 2nd and 3rd generation. Harwood Academic Publishers, Amsterdam;
17. (c) Moreira LM, dos Santos FV, Lyon JP et al (2008) Photodynamic therapy: porphyrins and phthalocyanines as photosensitizers. Aust J Chem 61(10):741-784
18. Marcus SL, McIntyre WR (2002) Photodynamic therapy systems and applications. Expert Opin Emerg Drugs 7(2):321-327
19. Oleinick NL, Antunez A, Clay M et al (1993) New phthalocyanine photosensitizers for photodynamic therapy. Photochem Photobiol 57:242-247
20. Dougherty TJ (1993) Photodynamic therapy. Photochem Photobiol 58:895-900
21. Siejak A, Wróbel D, Siejak P et al (2009) Spectroscopic and photoelectric investigations of resonance effects in selected sulfonated phthalocyanines. Dyes Pigm 83(3):281-290
22. Patterson MS, Wilson BC (1999) Photodynamic therapy. In: Dyh JV (ed) The modern technology of radiation oncology. Medical Physics Publishing, Madison
23. Foote CS (1999) Definition of type 1 and type II photosensitized oxidation. Photochem Photobiol 54:869-880
24. Frackowiak D, Planner A, Waszkowiak A et al (2001) Yield of ISC of Pc's evaluated on the basis of a time-resolved photothermal method. J Photochem Photobiol A Chem 141:101-108
25. Claessens GC, Blau WJ, Cook M et al (2001) Phthalocyanines and phthalocyanine analogues: The quest for applicable optical properties. Monat Chem 132:3-11
26. Petrásek Z, Phillips D (2003) A time-resolved study of concentration quenching of disulfonated aluminium phthalocyaninefluorescence. Photochem Photobiol Sci 2:236-244
27. (a) Berg K, Bommer JC, Moan J (1989) Evaluation of sulfonated aluminum phthalocyanines for use in photochemotherapy. A study on the relative efficiencies of photoinactivation. Photochem Photobiol 49(5):587-594;
28. (b) Rodrigues MMA, Simioni AR, Primo FL et al. (2009) Preparation, characterization and in vitro cytotoxicity of BSA-based nanosphere containing nanosized magnetic particles and/or photosensitizer. J Mag Mag Mater 321(10): 1600-1603
29. Nyokong T (2007) Effects of substituents on the photochemical and photophysical properties of main group metal phthalocyanines. Coord Chem Rev 251:1707-1722
30. Chan VS, Marshall JF, Svensen R, Phillips D, Hart JR (1987) Photosensitising activity of phthalocyanine dyes screened against tissue culture cells. Photochem Photobiol 45:757-761
31. Darwent JR, Douglas P, Harriman A et al (1982) Metal phthalocyanines and porphyrins as photosensitizers for reduction of water to hydrogen. Coord Chem Rev 44:83-126
32. Vincett PS, Voigt EM, Rieckhoff KE (1971) Phosphorescence and fluorescence of phthalocyanines. J Chem Phys 55:4131-4140
33. Dhami D, Phillips D (1996) Comparison of the photophysics of an aggregating and nonaggregating aluminium phthalocyanines. J Photochem Photobiol A Chem 100:77-84
34. Edrei R, Gottfried V, Van Lier JE et al (1998) Sulfonated phthalocyanines: photophysical properties, in vitro cell uptake and structure-activity relationships. J Porphyr Phthalocyanines 2:191-199
35. Ambroz M, Beeby A, MacRobert AJ, Simpson MSC et al (1991) Preparation, analytical andfluorescence spectroscopic studies-of sulphonated aluminium phthalocyanine photosensitizer. J Photochem Photobiol B Biol 9:87-95
36. Weber J, Busch D (1965) Complexes of 4,4 ¢ .4".4"-tetrasulfophthalocyanine. Inorg Chem 4:469-471
37. Huang Y, Xu G, Peng Y et al (2007) Zinc phthalocyanine tetrasulfonate (ZnPcS4): A new photosensitizer for photodynamic therapy in choroidal neovascularization. J Ocul Pharmacol Ther 23(4):377-386
38. Schmidt MH, Meyer GA, Reichert KW et al (2004) Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors. J Neurooncol 67:201-207
39. Josefsen LB, Boyle RW (2008) Photodynamic therapy and the development of metal-based photosensitizers. Met Based Drugs 2008:276109
40. Wagner JR, Ali H, Langlois R et al (1987) Biological activities of phthalocyanines VI. Photooxidation of l-tryptophan by selectively sulfonated gallium phthalocyanines: singlet oxygen yields and effect of aggregation. Photochem Photobiol 45:587-594
41. Wohrle W, Iskander N, Graschew G (1990) Synthesis of positively charged phthalocyanines and their activity in the photodynamic therapy of cancer cells. Photochem Photobiol 51:351-356
42. Ogunsipe A, Nyokong T (2005) Light-induced effects in sulfonated aluminum phthalocyanines-potential photosensitizers in the photodynamic therapy. Photochem Photobiol Sci 4:510-516
43. Foley MS, Beeby A, Parker AW et al (1997) Excited triplet state photophysics of the sulphonated aluminium phthalocyanines bound to human serum albumin. J Photochem Photobiol B 38(1):10-17
44. Kuznetsova NA, Gretsova NS, Derkacheva VM et al (2003) Sulphonated phthalocyanines: aggregation and singlet oxygen quantum yield in aqueous solutions. J Porphyr Phthalocyanines 7:147-154
45. Frackowiak D, Ion RM, Waszkowiak A (2002) Spectral properties of phthalocyanines oriented in stretched polymerfilms. J Phys Chem B 106:13154-13160
46. Sharman WM, Allen CM, Van Lier JE (2000) Role of activated oxygen species in photodynamic therapy. Methods Enzymol 319:376-400
47. (a) Spikes JK (1986) Phtalocyanines as photosensitizers in biological systems and for the photodynamic therapy of tumors. Photochem Photobiol 43:691-699;
48. (b) de Castro Pazos, Pacheco-Soares C, da Silva NS et al (2003) Ultrastructural effects of two phthalocyanines in CHO-K1 and HeLa cells after laser irradiation. Biocell 27(3):301-309;
49. (c) Kessel D (1997) Subcellular localization of photosensitizing agents. Photochem Photobiol 65:387-388
50. Wrobel D, Boguta A, Wojcik A et al (2005) Time-resolved photocurrent generation in a photoelectrochemical cell with phthalocyanine. Spectrochim Acta Part A Mol Biomol Spectrosc 61(6):1127-1132
51. Kim JS et al (2003) Mitochondrial permeability transition: A common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 304:463-470
52. Oleinick NL, Evans HH (1998) The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 150(5 Suppl):S146-S156
53. Nowis D, Makowski M, Stokłosa T et al (2005) Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol 52(2):339-345
54. Triesscheijn M, Baas P, Schellens JHM et al (2006) Photodynamic therapy in oncology. Oncologist 11:1034-1044
55. Abels C (2004) Targeting of the vascular system of solid tumors by photodynamic therapy (PDT). Lancet Oncol 5:497-508
56. (a) Vancikova Z (1998) Principles of the photodynamic therapy and its impact on the immune system. Sb Lek 99:1-15;
57. (b) Machado AHA, Soares CP, da Silva NS et al (2009) Cellular and molecular studies of the initial process of the photodynamic therapy in HEp-2 cells using LED light source and two different photosensitizers. Cell Biol Int 33(7):785-795
58. Sibata CH, Colussi VC, Oleinick NL et al (2001) Photodynamic therapy in oncology. Expert Opin Pharmacother 2:1-11
59. Gad F, Zahra T, Francis KP et al (2004) Targeted photodynamic therapy of established soft tissue infections in mice. Photochem Photobiol Sci 3:451-458
60. Fingar VH (1996) Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14:323-328
61. Ion RM, Grigorescu M, Scarlat F et al (2001) Porphyrin sensitization of DNA. Rom J Phys 46:637-646
62. Alexandrova R, Stoykova E, Ion RM (2004) Photodynamic therapy of cancer. Exp Pathol Parasitol 7(3):3-23
63. Ion RM (2010) Derivative UV-VIS spectrophotometry for porphyrins interactions in photodynamic therapy. Anal Lett 43(7 & 8):1277-1286
64. Bown SG, Tralau CJ, Coleridge Smith PD et al (1986) Photodynamic therapy with porphyrin and phthalocyanine sensitisation: Quantitative studies in normal rat liver. Br J Cancer 54:43-52
65. Ion RM, Fierascu RC, Neagu M et al (2010) Porphyrin (TPP)-polyvinylpyrrolidone (PVP)-fullerene (C 60 ) triad as novel sensitizer in photodynamic therapy. Sci Adv Mater 2(2):223-229(7)
66. Wrobel D, Boguta A (2002) Study of the influence of substituents on spectroscopic and photoelectric properties of zinc phthalocyanines. J Photochem Photobiol A Chem 150:67-76
67. Filip AG, Clichici S, Daicoviciu D et al (2011) Possible in vivo mechanisms involved in photodynamic tharapy using tetrapyrrolic macrocycles. Braf J Med Biol Res 44(1):13-61
68. Anbazhagan V, Asha Jhonsi M, Renganathan R (2009) Interaction of meso-tetrakis (p-sulfonatophenyl) porphyrin (TPPS 4 ) with pyrimidines: A steady state and time-resolvedfluorescence quenching study. J Mol Struct 919:79-82
69. (a) Ion RM (1999) Spectral analysis of the porphyrins incorporation into human blood. J Biomed Optics 4:319-327;
70. (b) Ferreira J, Kurachi C, Moriyama LT et al (2006) Correlation between the photostability and photodynamic efficacy for different photosensitizers. 3(2): 91-95
71. (a) Ion RM, Boda D (2008) Supramolecular nanotubes porphyrin-based generated by aggregation process. Rev Chim (Bucharest) 59(2):205-207;
72. (b) Bonnett R, Martinez G (2001) Photobleaching of sensitizers used in photodynamic therapy. Tetraedron 57:9513-9547;
73. (c) Ion RM, Mandravel C (1997) Some aspects about the porphyrins photodegradation. South J Braz Chem Soc V:111-129
74. Ion RM, Ionita MA, Carstocea et al (2004) Clinical aspects of photodynamic therapy-Romanian experience. Oftalmologia 48(2):53-61
75. Wickens J, Blinder KJ (2006) A preliminary benefit-risk assessment of verteporfin in agerelated macular degeneration. Drug Saf 29(3):189-199
76. Petermeier K, Tatar O, Inhoffen W et al (2006) Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes. Br J Ophthalmol 90:1034-1039
77. Ionita MA, Ion RM, Carstocea B (2003) Photochemical and photodynamic properties of vitamin B2-riboflavin in liposomes. Oftalmologia 58(3):29-34
78. Ionita MA, Ion RM, Carstocea B et al (2002) Photodynamic occlusion of ocular neovascularization with B2 vitamin. Oftalmologia XLXIV(3):82-86
79. Borgatti-Jeffreys A, Hooser SB, Miller MA et al (2007) Phase I clinical trial of the use of zinc phthalocyanine tetrasulfonate as a photosensitizer for photodynamic therapy in dogs. Am J Vet Res 68(4):399-404
80. Huang Y, Xu G, Peng Y et al (2009) Photodynamic effects of ZnPcS 4-BSA in human retinal pigment epithelium cells. J Ocul Pharmacol Ther 25(3):231-238
81. Avetisov SE, Budzinskaia MV, Likhvantseva VG et al (2005) Thefirst results of phase IIA of clinical studies of photodynamic therapy for subretinal neovascular membranes with photosense. Vestn Oftalmol 121(5):6-9
82. Josefsen LB, Boyle RW (2008) Photodynamic therapy and the development of metal-based photosensitizers. Met Based Drugs 2008:276109
83. Miller JW, Stinson WG, Gregory WA et al (1991) Phthalocyanine photodynamic therapy of experimental iris neovascularization. Ophthalmology 98(11):1711-1719
84. Kliman GH, Puliafito CA, Grossman GA et al (1994) Retinal and choroidal vessel closure using phthalocyanine photodynamic therapy. Laser Surg Med 15(1):11-18
85. Grant WE, Speight PM, MacRobert AJ et al (1994) Photodynamic therapy of normal rat arteries after photosensitisation using disulphonated aluminium phthalocyanine and 5-aminolaevulinic acid. Br J Cancer 70(1):72-78
86. Lilge L, Portnoy M, Wilson BC (2000) Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumour tissue. Br J Cancer 83(8):1110-1117
87. Muller PJ, Wilson BC (1996) Photodynamic therapy for malignant newly diagnosed supratentorial gliomas. J Clin Laser Med Surg 14:263-270
88. Muller PJ, Wilson BC (1992) Photodynamic therapy for brain tumors. In: McCaughan JS (ed) A clinical manual: photodynamic therapy of malignancies. RG Landes Co, Boca Raton, pp 201-211
89. Lilge L, Olivo MC, Schatz SW et al (1996) The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy. Br J Cancer 73:332-343
90. Chen Q, Chopp M, Madigan L et al (1996) Damage threshold of normal rat brain in photodynamic therapy. Photochem Photobiol 64:163-167
91. Farrell TJ, Wilson BC, Patterson MS et al (1998) Comparison of the in vivo photodynamic threshold dose for photofrin, mono-and tetrasulfonated aluminum phthalocyanine using a rat liver model. Photochem Photobiol 68:394-399
92. Yoshida Y, Dereski MO, Garcia JH et al (1992) Neuronal injury after photoactivation of photofrin II. Am J Pathol 141:989-997
93. Majno G, Joris I (1995) Apoptosis, oncosis and necrosis: an overview of cell death. Am J Pathol 146:3-15
94. White E (1996) Pathway of regulation of apoptosis: overview of apoptosis. Calbiochem Novabiochem Int 1:8-15
95. Wong CS, Van Dyk J, Milosevic M et al (1994) Radiation myelopathy following single courses of radiotherapy and retreatment. Int J Radiat Oncol Biol Phys 30:575-581
96. Schultheiss TE, Kun LE, Ang KK et al (1995) Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 31:1093-1112
97. Laperriere NJ, Cerezo L, Milosevic MF et al (1997) Primary lymphoma of brain: results of management of a modern cohort with radiation therapy. Radiother Oncol 43:247-252
98. Li YQ, Guo YP, Jay V et al (1996) Time course of radiation induced apoptosis in the adult rat spinal cord. Radiother Oncol 39:35-42
99. Chan WS, Brasseur N, La Madeleine C et al (1996) Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulphonated aluminum phthalocyanine or photofrin: tumor cell survival and bloodflow. Anticancer Res 16:1887-1892
100. (a) Margaron P, Madarnas P, Quellet R et al (1996) Biological activities of phthalocyanines. XVII histopathologic evidence for different mechanisms of EMT-6 tumor necrosis induced by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin. Anticancer Res 16:613-620;
101. (b) Tyrrell RM (1996) Oxidant, antioxidant status and photocarcinogenesis: The role of gene activation. Photochem Photobiol 63:380-383
102. Medina WSG, dos Santos NAG, Curti C et al (2009) Effects of zinc phthalocyanine tetrasulfonate-based photodynamic therapy on rat brain isolated mitochondria. Chem Biol Interact 179(2-3):402-406
103. Kostron H, Obwegeser A, Jakober R (1996) Photodynamic therapy in neurosurgery: A review. J Photochem Photobiol B Biol 36:157-168
104. Lilge L, Ching E, Portnoy M, Molckovsky A, Wilson BC (2000) Photofrin mediated PDT in normal rat brain: assessment of apoptosis as a quantitative biological endpoint. Proc SPIE 3909:45-52
105. Mahaley MS, Mettlin C, Matarajan N, Law ER, Peace B (1989) National survey of patterns of care for brain-tumour patients. J Neurosurg 71:826-836
106. Muller P, Wilson B (1991) Photodynamic therapy of brain tumors: postoperative 'field fractionation'. J Photochem Photobiol B Biol 9:117-119
107. Origitano TC, Reichman OH (1993) Photodynamic therapy for intracranial neoplasms: development of an image-based computer-assisted protocol for photodynamic therapy of intracranial neoplasms. Neurosurgery 32:587-595
108. Popovic EA, Kaye AH, Hill JS (1996) Photodynamic therapy of brain tumors. J Clin Laser Med Surg 14:251-261
109. Pascu ML, Popescu A, Carp N et al (2000) Photodynamic therapy studies on brain tumors using nitrogen pulsed lasers. Proc SPIE 4166:140-145
110. Van den Brink-de Vries NA, Beijnen JH et al (2006) Blood-brain barrier and chemotherapeutic treatment of brain tumors. Exp Rev Neurother 6:1199-1209
111. (a) Danaila L, Pascu ML, Popescu A et al (2000) Spectrophotometric characterization of useful dyes in laser photodynamic therapy of cancer. Proc SPIE 4068:712-718;
112. (b) Pascu ML, Danaila L, Popescu A et al (1999) Researches concerning the application of laser photodynamic therapy in neurosurgery. Rom Rep Phys 2:38-45
113. Butler JM, Rapp SR, Shaw EG (2006) Managing the cognitive effects of brain tumor radiation therapy. Curr Treat Options Oncol 7:517-523
114. Zhang X, Jiang F, Kalkanis SN et al (2006) Combination of surgical resection and photodynamic therapy of 9L gliosarcoma in the nude rat. Photochem Photobiol 82:1704-1711
115. Lam M, Oleinick NL, Nieminen AL (2001) Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells. Reactive oxygen species and mitochondrial inner membrane permeabilization. J Biol Chem 276:47379-47386
116. Madsen SJ, Angell-Petersen E, Spetalen S et al (2006) Photodynamic therapy of newly implanted glioma cells in the rat brain. Lasers Surg Med 38:540-548
117. Liu W, Chen N, Jin H et al (2007) Intravenous repeated-dose toxicity study of ZnPcS 2 P 2-based-photodynamic therapy in beagle dogs. Regul Toxicol Pharmacol 47:221-231
118. (a) Schmidt MH, Meyer GA, Reichert KW et al (2004) Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors. J Neurooncol 67:201-207;
119. (b) Dereski MO, Madigan L, Chopp M (1995) Brain response to photodynamic therapy with Photofrin, nonsulfonated aluminum phthalocyanine and tin purpurin. Proc SPIE 2371: 579-581
120. Hopper C, Kubler A, Lewis H et al (2004) mTHPC mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer 111:138-146
121. (a) Allen CM, Langlois R, Sharman WM et al (2002) Photodynamic properties of amphiphilic derivates of aluminum tetrasulfophthalocyanine. Photochem Photobiol 76(2):208-216;
122. (b) Ketabchi A, MacRobert A, Speight PM et al (1998) Induction of apoptotic cell death by photodynamic therapy in human keratinocytes. Arch Oral Biol 43(2):143-149;
123. (c) Dilkes MG, Benjamin E, Ovaisi S et al (2003) Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases. J Laryng Otol 117:713-717
124. Peng Q, Moan J, Nesland JM et al (1990) Aluminum phthalocyanines with asymmetrical lower sulfonation and with symmetrical higher sulfonation: A comparison of localizing and photosensitizing mechanism in human tumor LOX xenografts. Int J Cancer 46(4):719-726
125. Inés Yslas E, Prucca C, Romanini S et al (2009) Biodistribution and phototherapeutic properties of Zinc (II) 2,9,16,23-tetrakis (methoxy) phthalocyanine in vivo . Photodiagn Photodyn Ther 6:62-70
126. (a) Spencer JM, Henry M. (2010) Actinic keratosis. e Medi cine: http://emedicine.medscape. com/23July ;
127. (b) Boda D, Neagu M, Constantin C et al (2009) New photosensitizers versus aminolevulinic acid (ALA) in experimental photodynamic therapy of actinic keratosis-A case report. Anal Sci Univ AI Cuza Gen Molec Biol X:61-69
128. Kiesslich T, Krammer B, Plaetzer K (2006) Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. Curr Med Chem 13:2189-2204
129. Berlanda J, Kiesslich T, Oberdanner CB et al (2006) Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells. J Environ Pathol Toxicol Oncol 25:173-188
130. Berg K, Bommer JC, Moan J (1989) Evaluation of sulfonated aluminum phthalocyanines for use in photochemotherapy. A study on the relative efficiencies of photoinactivation. Photochem Photobiol 49:587-594
131. Love WG, Havenaar EC, Lowe PJ et al (1994) Uptake of zinc(II)-phthalocyanine by HepG2 cells expressing the low density lipoprotein receptor: studies with the liposomal formulation CGP55847. Proc SPIE 2078:381-388
132. Neagu M, Manda C, Constantin C et al (2007) Structural differences of porphyrins in photodynamic therapy induces distinct antineoplastic effects. J Porphyr Phthalocyanines 01:58-67
133. Guery JC, Sette A, Dragomir A et al (1992) Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I evidence for in vivo MHC blocade preventing T cell activation. J Exp Med 175:1345-1354
134. Vermes I, Haanen C, Steffens-Nakken H et al (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells usingfluorescein labeled Annexin V. J Immunol Methods 184:39-51
135. Fernandes-Alnemri T, Armstrong RC, Krebs J et al (1996) In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci USA 93:7464-7469
136. Shapiro HM (2001) Optical measurement in cytometry: light scattering, extinction, absorption andfluorescence. Methods Cell Biol 63:107-129
137. Weaver JL (2000) Introduction toflow cytometry. Methods 21:199-201
138. Tənase C, Codorean E, ArdeleanuC et al (2004) Experimental Model of Antitumoral Photodynamic Therapy with Phthalocyanines-Pathological Evaluation. In: Soares F, Vassallo J, Bleggi Torres LF (eds) Proc. 2nd Intercontinental Congress of Pathology, pp 117-120
139. (a) Chan WS, Marshall JF, Svensen R et al (1987) Photosensitizing activity of phthalocyanine dyes screened against tissue culture cells. Photochem Photobiol 45:757-761;
140. (b) van Bruggen N, Chan WS, Syha J et al (1992) Cell and tissue response of a murine tumour to phthalocyaninemediated photodynamic therapy. Eur J Cancer 28:4246-4249;
141. (c) Perrin Tamietti BF, Machado AHA, Maftoum-Costa M et al (2007) Analysis of mitochondrial activity related to cell death after PDT with AlPcS4. Photomed Laser Surg 25(3):175-179
142. Simstein R, Burow M, Parker A et al (2003) Apoptosis, chemoresistance, and breast cancer: insight from the MCF-7 cell model system. Exp Biol Med 228:995-1003
143. (a) Alexandrova R, Stoykova E, Ion RM et al (2005) In vitro cytotoxicity assessment of phthalocyanines on virus-transformed animal cells. Proc SPIE 5830:404-408;
144. (b) Rumie Vittar NB, Awruch J, Azizuddin K et al (2010) Caspase-independent apoptosis, in human MCF-7c3 breast cancer cells, following PDT, with a novel water-soluble phthalocyanine. Int J Biochem Cell Biol 42:1123-1131
145. Yslas EI, Prucca C, Romanini S et al (2009) Biodistribution and phototherapeutic properties of Zinc (II) 2, 9, 16, 23-tetrakis (methoxy) phtalocyanine in vivo. Photodiagn Photodyn Ther 6(1):62-70
146. Alexandrova R, Sabotinov O, Stoykova E et al (2004) In vitro cytotoxicity assessment of [5,10,15,20-tetra (4-sulfophenyl) porphyrin] on tumor and non-tumor cell lines. Proc SPIE 5449:227-234
147. Perzelova A, Macicova I, Mraz P et al (1998) Characterization of two new permanent glioma cell lines 8-MG-BA and 42-MG-BA. Neoplasma 42:25-29
148. Pop SF, Ion RM, Neagu M et al (2010) Photodynamic therapy on B16 cells with tetrasulphonated porphyrin and different light sources. J Mater Sci Eng 4(3):10-16
149. Wang JC (2009) Untangling the double helix. DNA entanglement and the action of the DNA topoisomerases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
150. Spitzner JR, Muller MT (1988) A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acids Res 16(12):5533-5556
151. Muller MT, Spitzner JR, DiDonato JA et al (1988) Single-strand DNA cleavages by eukaryotic topoisomerase II. Biochemistry 27(22):8369-8379
152. Brown WM (1980) Polymorphism in mitochondrial DNA of humans as revealed by restriction endonuclease analysis. PNAS 77(6):3605-3609
153. Chan WS, West CML, Moore JV et al (1991) Photocytotoxic efficacy of sulphonated species of aluminium phthalocyanine against cell monolayers, multicellular spheroids and in viva tumours. Br J Cancer 64:827-832
154. van Lier JB (1990) Phthalocyanines as photodynamic sensitizers. In: Kessel D (ed) Photodynamic therapy of neoplastic disease, vol 1. CRC Press, Boca Raton, pp 279-291
155. Tralau CJ, MacRobert AJ, I'D C-S et al (1987) Photodynamic therapy with phthalocyanine sensitization: quantitative studies in a transplantable ratfibrosarcoma. Br J Cancer 55:389-395
156. Chan WS, Marshall JF, Hart IR (1987) Photodynamic therapy of a murine tumour following sensitization with chloro aluminum sulfonated phthalocyanine. Photochem Photobiol 46:867-871
157. Brasseur N, Ali H, Langlois R et al (1987) Biological activities of phthalocyanines-V. Photodynamic therapy of EMT6 mammary tumours in mice with sulfonated phthalocyanines. Photochem Photobiol 45:581-586
158. Milanesi C, Zhou C, Biolo R et al (1990) Zn(II)-phthalocyanine as a photodynamic agent for turnouts. II. Studies on the mechanism of photosensitised tumour necrosis. Br J Cancer 61:846-850
159. Ben-Hur E, Rosenthal I (1986) Photosensitization of Chinese hamster cells by water-soluble phthalocyanines. Photochem Photobiol 43:615-619
160. Canti G, France P, Marelli O et al (1990) Comparative study of the therapeutic effect of photoactivated hematoporphyrin derivative and aluminium disulfonated phthalocyanines on tumor bearing mice. Cancer Lett 53:123-127
161. I' M, Madarnas P, Ouellet R et al (1996) Biological activities of phthalocyanines XVII. Histopathological evidence for different mechanisms of EMT-6 tumor necrosis induced by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin. Anticancer Res 16:613-620
162. Ali H, Langlois R, Wagner JR et al (1988) Biological activities of phthalocyanines-X. Synthesis and analyses of sulfonated phthalocyanines. Photochem Photobiol 47:713-717
163. Boyle RW, Leznoff CC, van Lier JE (1993) Biological activities of phthalocyanines-XVI. Tetrahydroxy-and tetraalkylhydroxy zinc phthalocyanines. Effect of alkyl chain length on in vitro and in vivo photodynamic activities. Br J Cancer 67(6):1177-1181
164. Brasseur N, Ali H, Langlois R et al (1987) Biological activities of phthalocyanines-VII. Photoinactivation of V-79 Chinese hamster cells, by selectively sulfonated gallium phthalocyanines. Photochem Photobiol 46:739-745
165. Brasseur N, Ali H, Langlois R et al (1987) Biological activities of ohthalocyanines-V. Phoiodynamic therapy of EMT-i mammary tumors in mice with sulfonated phthalocyanines. Photochem Photobiol 45:581-590
166. Brasseur N, Ali H, Langlois R et al (1988) Biological activities of phthalocyanines-IX. Photosensitization of V-79 Chinese hamster cells and EMT-6 mouse mammary tumor by selectively sulfonated zinc phthalocyanines. Photochem Photobiol 41:705-712
167. Rousseau J, Boyle RW, Maclennan AH et al (1991) Biodistribution and tumor uptake of [67Ga]chlorogallium-tetraoctadecyloxy phthalocyanine and its sulfonation products in tumor bearing C3H mice. 1991. Int J Radiat Appl Instrum Part B Nucl Med Biol 18(7):777-782
168. Langlois R, Ali H, Brasseur N et al (1986) Biological activities of phthalocyanines-IV. Type II sensitized photooxidation of L-tryptophan and cholesterol by sulfonated metallophthalocyanines. Photochem Photobiol 44:117-125
169. Winkelman J, Spicer SS (1962) The metachromatic interaction of biebrich scarlet with histone and other cationic polymers. J Histochem Cytochem 11(4):489-492
170. Kim HR, Luo Y, Li G et al (1999) Enhanced apoptotic response to photodynamic therapy with bcl-2 transfection. Cancer Res 59:3429-3432
171. Kessel D, Castelli M (2001) Evidence that bcl-2 is the target of three photosensitizers that induce a rapid apoptotic response. Photochem Photobiol 74:318-322
172. Morris RL, Azizuddin K, Lam M et al (2003) Fluorescence resonance energy transfer reveals a binding site of a photosensitizer for photodynamic therapy. Cancer Res 63:5194-5197
173. Usuda J, Chiu SM, Azizuddin K et al (2002) Promotion of photodynamic therapy-induced apoptosis by the mitochondrial protein Smac/DIABLO: dependence on Bax. Photochem Photobiol 76:217-223
174. Xue L, He J, Oleinick NL (1999) Promotion of photodynamic therapy-induced apoptosis by stress kinases. Cell Death Differ 6:855-864
175. Xue LY, Chiu SM, Oleinick NL (2001) Photodynamic therapy-induced death of MCF-7 human breast cancer cells: A role for caspase-3 in the late steps of apoptosis but not for the critical lethal event. Exp Cell Res 263:145-155
176. Xue LY, Chiu SM, Oleinick NL (2001) Photochemical destruction of the Bcl-2 oncoprotein during photodynamic therapy with the phthalocyanine photosensitizer Pc4. Oncogene 20:3420-3427
177. Xue LY, Qiu Y, He J et al (1999) Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. Oncogene 18:3391-3398
178. Furre IE, Shahzidi S, Luksiene Z et al (2005) Targeting PBR by hexaminolevulinate-mediated photodynamic therapy induces apoptosis through translocation of apoptosis-inducing factor in human leukemia cells. Cancer Res 65:11051-11060
179. Ichinose S, Usuda J, Hirata T et al (2006) Lysosomal cathepsin initiates apoptosis, which is regulated by photodamage to Bcl-2 at mitochondria in photodynamic therapy using a novel photosensitizer, ATX-s10 (Na). Int J Oncol 29:349-355
180. Ji Z, Yang G, Vasovic V et al (2006) Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines. J Photochem Photobiol B Biol 84:213-220
181. Kessel D (2002) Relocalization of a cationic porphyrin during photodynamic therapy. Photochem Photobiol Sci 1:837-840
182. Kessel D, Luo Y (2005) Intracellular sites of photodamage as a factor in apoptotic cell death. J Porphyr Phthalocyanines 5:181-184
183. Kriska T, Korytowski W, Girotti AW (2002) Hyperresistance to photosensitized lipid peroxidation and apoptotic killing in 5-aminolevulinate-treated tumor cells overexpressing mitochondrial GPX4. Free Radic Biol Med 33:1389-1402
184. Zawacka-Pankau J, Issaeva N, Hossain S et al (2007) Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and independent manner. J Biol Chem 282:2466-2473
185. Moan J, Berg K (1991) The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 53:549-553
186. Kessel D, Luo Y, Deng Y, Chang CK (1997) The role of subcellular localization in initiation of apoptosis by photodynamic therapy. Photochem Photobiol 65:422-426
187. Xue LY, Chiu SM, Fiebig A et al (2003) Photodamage to multiple Bcl-xL isoforms by photodynamic therapy with the phthalocyanine photosensitizer Pc4. Oncogene 22:9197-9204
188. Yslas EI, Prucca C, Romanini S et al (2009) Biodistribution and phototherapeutic properties of Zinc (II) 2, 9, 16, 23-tetrakis (methoxy) phtalocyanine in vivo. Photodiagn Photodyn Ther 6(1):62-70
189. Krestyn E, Kolarova H, Bajgar R et al (2010) Photodynamic properties of ZnTPPS 4 , ClAlPcS 2 and ALA in human melanoma G361 cells. Toxicol In Vitro 24:286-291
190. (a) Liu MO, Tai CH, Sain MZ et al (2004) Photodynamic applications of phthalocyanines. J Photochem Photobiol A: Chem 165:131-136;
191. (b) Machado AH, Braga FM, Soares CP et al (2007) Photodynamic therapy a new photosensitizing agent. Photomed Laser Surg 25(3):220-228